{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:10:42Z","timestamp":1792012242762,"version":"4.4.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1995,3,1]],"date-time":"1995-03-01T00:00:00Z","timestamp":794016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[1995,3]]},"DOI":"10.1007\/bf01875052","type":"journal-article","created":{"date-parts":[[2005,7,2]],"date-time":"2005-07-02T20:21:01Z","timestamp":1120335661000},"page":"31-41","source":"Crossref","is-referenced-by-count":4,"title":["Corticosteroid receptor antagonists: A current perspective"],"prefix":"10.1007","volume":"17","author":[{"given":"Win","family":"Sutanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ronald","family":"Kloet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF01875052_CR1","first-page":"95","volume":"12","author":"ER Kloet de","year":"1991","unstructured":"de Kloet ER. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 1991;12:95\u2013164.","journal-title":"Front Neuroendocrinol"},{"key":"BF01875052_CR2","first-page":"1458","volume":"3","author":"JW Funder","year":"1990","unstructured":"Funder JW. Target tissue specificity of mineralocorticoids. Trends Endocrinol Metab 1990;3:1458.","journal-title":"Trends Endocrinol Metab"},{"key":"BF01875052_CR3","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1210\/endo.132.6.8504732","volume":"132","author":"CB Whorwood","year":"1993","unstructured":"Whorwood CB, Sheppard MC, Stewart PM. Licorice inhibits 11\u03b2-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 1993;132:2287\u201392.","journal-title":"Endocrinology"},{"key":"BF01875052_CR4","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1517\/13543776.1.12.1775","volume":"Dec","author":"W Sutanto","year":"1991","unstructured":"Sutanto W, de Kloet ER. Novel analogues of mineralocorticoids, antimineralocorticoids and related compounds. Curr Opin Ther Pat 1991;Dec:1775\u201391.","journal-title":"Curr Opin Ther Pat"},{"key":"BF01875052_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.2610110604","volume":"11","author":"W Sutanto","year":"1991","unstructured":"Sutanto W, de Kloet ER. Mineralocorticoid receptor ligands: Biochemical, pharmacological, and clinical aspects. Med Res Rev 1991;11:1\u201323.","journal-title":"Med Res Rev"},{"key":"BF01875052_CR6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/1043-2760(93)90074-O","volume":"4","author":"A Guiochon-Mantel","year":"1993","unstructured":"Guiochon-Mantel A, Milgrom E. Cytoplasmic-nuclear trafficking of steroid hormone receptors. Trends Endocrinol Metab 1993;4:322\u20138.","journal-title":"Trends Endocrinol Metab"},{"key":"BF01875052_CR7","first-page":"597","volume":"7","author":"R Rupprecht","year":"1993","unstructured":"Rupprecht R, Arriza JL, Spengler D, Reul JMHM, Evans RM, Holsboer F, Damm K. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol 1993;7:597\u2013603.","journal-title":"Mol Endocrinol"},{"key":"BF01875052_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0960-0760(93)90052-X","volume":"47","author":"APH Wright","year":"1993","unstructured":"Wright APH, Zilliacus J, McEwan IJ, Dahlman-Wright K, Alml\u00f6f T, Carlstedt-Duke J, et al.. Structure and function of the glucocorticoid receptor. J Ster Biochem Mol Biol 1993;47:11\u20139.","journal-title":"J Ster Biochem Mol Biol"},{"key":"BF01875052_CR9","first-page":"105","volume":"25","author":"BW O'Malley","year":"1969","unstructured":"O'Malley BW, McGuire WL, Kohler PO, Korenman SG. Studies on the mechanism of steroid hormone regulation of synthesis of specific proteins. Rec Prog Horm Res 1969; 25:105\u201360.","journal-title":"Rec Prog Horm Res"},{"key":"BF01875052_CR10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/oxfordjournals.humrep.a138524","volume":"9","author":"M-C Lebeau","year":"1994","unstructured":"Lebeau M-C, Baulieu EE. Steroid antagonists and receptorassociated proteins. Hum Reprod 1994;9:437\u201344.","journal-title":"Hum Reprod"},{"key":"BF01875052_CR11","first-page":"326","volume":"3","author":"DF Smith","year":"1993","unstructured":"Smith DF, Toft DO. Steroid receptor and their associated proteins. Mol Endocrinol 1993;3:326\u201333.","journal-title":"Mol Endocrinol"},{"key":"BF01875052_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0960-0760(94)90076-0","volume":"48","author":"F Cadepond","year":"1994","unstructured":"Cadepond F, Jibard N, Binart N, Schweizer-Groyer G, Segard-Maurel I, Baulieu EE. Selective deletions in the kDa heat shock protein (hsp 90) impede hetero-oligomeric complex formation with the glucocorticosteroid receptor (GR) or hormone binding by GR. J Ster Biochem Mol Biol 1994;48:361\u20137.","journal-title":"J Ster Biochem Mol Biol"},{"key":"BF01875052_CR13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1432-1033.1985.tb08945.x","volume":"149","author":"A Groyer","year":"1985","unstructured":"Groyer A, Le Bouc Y, Joab I, Radanyi C, Renoir JM, Robel P. Chick oviduct glucocorticosteroid receptor. Specific binding of RU 486 and immunological studies with antibodies to chick oviduct progesterone receptor. Eur J Biochem 1985; 149:445\u201351.","journal-title":"Eur J Biochem"},{"key":"BF01875052_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0039-128X(89)90142-6","volume":"53","author":"JM Renoir","year":"1989","unstructured":"Renoir JM, Radanyi C, Baulieu EE. The antiprogesterone RU 486 stabilizes the heterooligomeric, non DNA-binding, 8S form of the rabbit uterus cytosol progesterone receptor. Steroids 1989;53:1\u201320.","journal-title":"Steroids"},{"key":"BF01875052_CR15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.1702904","volume":"251","author":"SL Schreiber","year":"1991","unstructured":"Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283\u20137.","journal-title":"Science"},{"key":"BF01875052_CR16","first-page":"15","volume-title":"Adrenal steroid antagonism","author":"WL Duax","year":"1984","unstructured":"Duax WL, Griffin JF. Structural characteristics of antagonists for gluco- and mineralocorticoids. In: Agarwal MK, editor. Adrenal steroid antagonism. Berlin: Walter de Gruyter, 1984:15\u201341."},{"key":"BF01875052_CR17","first-page":"169","volume-title":"Drug designs","author":"JP Raynaud","year":"1978","unstructured":"Raynaud JP, Ojasoo T, Bouton MM, Philibert D. Receptor binding as a tool in the development of new bioactive steroids. In: Ariens EJ, editor. Drug designs. New York: Academic Press, 1978:169\u2013214."},{"key":"BF01875052_CR18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/0006-2952(83)90469-0","volume":"32","author":"G Wambach","year":"1983","unstructured":"Wambach G, Casals-Stenzel J. Structure-activity relationship of new steroidal aldosterone antagonists. Comparison of the affinity for mineralocorticoid receptorsin vitro and the antialdosterone activityin vivo. Biochem Pharmacol 1983; 32:1479\u201385.","journal-title":"Biochem Pharmacol"},{"key":"BF01875052_CR19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0960-0760(92)90430-Q","volume":"41","author":"ME Rafestin-Oblin","year":"1992","unstructured":"Rafestin-Oblin ME, Lombes M, Coutte B, Baulieu EE. Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp 90 release from mineralocorticoid receptor. J Ster Biochem Mol Biol 1992;41:815\u201321.","journal-title":"J Ster Biochem Mol Biol"},{"key":"BF01875052_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1042\/bj2820697","volume":"282","author":"B Coutte","year":"1992","unstructured":"Coutte B, Lombes M, Baulieu EE, Rafestin-Oblin ME. Aldosterone antagonists destabilize the mineralocorticoid receptor. Biochem J 1992;282:697\u2013702.","journal-title":"Biochem J"},{"key":"BF01875052_CR21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0006-291X(87)90679-6","volume":"143","author":"MK Agarwal","year":"1987","unstructured":"Agarwal MK, Kalimi M. Activation of mineralocorticoid agonist and antagonist specific receptors from rat kidney. Biochem Biophys Res Commun 1987;143:398\u2013402.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF01875052_CR22","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1210\/endo-104-6-1839","volume":"104","author":"GB Cutler Jr","year":"1979","unstructured":"Cutler GB Jr, Barnes KM, Sauer MA, Loriaux DL. 11-Deoxycortisol: a glucocorticoid antagonistin vivo. Endocrinology 1979;104:1839\u201346.","journal-title":"Endocrinology"},{"key":"BF01875052_CR23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/279158a0","volume":"279","author":"GG Rousseau","year":"1979","unstructured":"Rousseau GG, Kirchoff J, Formstecher P, Lustenberger P. 17\u03b2-Carboxamide steroids are a new class of glucocorticoid antagonists. Nature 1979;279:158\u20139.","journal-title":"Nature"},{"key":"BF01875052_CR24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1210\/endo-107-2-472","volume":"107","author":"GP Chrousos","year":"1980","unstructured":"Chrousos GP, Barnes KM, Sauer MA, Loriaux DL, Cutler GB Jr. \u03941,9(11)-11-Deoxycortisol: an improved glucocorticoid antagonist. Endocrinology 1980;107:472\u20138.","journal-title":"Endocrinology"},{"key":"BF01875052_CR25","series-title":"Proceedings of the 6th Annual Clinical Symposium","first-page":"152","volume-title":"Progress in research and clinical applications of corticosteroids","author":"GP Chrousos","year":"1982","unstructured":"Chrousos GP, Cutler GB Jr, Simons SS Jr, Pons M, John LS, Moriarty RM, et al. Development of antiglucocorticoids with potential clinical usefulness. In: Lee HJ, Fitzgerald TJ, editors. Progress in research and clinical applications of corticosteroids. Proceedings of the 6th Annual Clinical Symposium, Philadelphia: Heyden, 1982;152."},{"key":"BF01875052_CR26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0039-128X(82)90020-4","volume":"40","author":"GP Chrousos","year":"1982","unstructured":"Chrousos GP, Sauer MA, Loriaux DL, Cutler GM Jr. \u0394-11-Oxa-11-deoxycortisol: a new antiglucocorticoid with activityin vivo. Steroids 1982;40:425\u20139.","journal-title":"Steroids"},{"key":"BF01875052_CR27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0022-4731(83)90097-3","volume":"18","author":"GG Rousseau","year":"1983","unstructured":"Rousseau GG, Cambron P, Brasseur N, Marcotte L, Matton P, Schmit J-P. Glucocorticoid agonist and antagonist activity of 17,21-acetonide steroids. J Ster Biochem 1983; 18:237\u201343.","journal-title":"J Ster Biochem"},{"key":"BF01875052_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000419634","volume":"19","author":"D Philibert","year":"1991","unstructured":"Philibert D, Costerousse G, Gaillard-Moguilewsky M, Nedelec L, Nique F, Tournemine C, et al.. From RU 38486 towards dissociated antiglucocorticoid and antiprogesterone. Front Horm Res 1991, 19:1\u201317.","journal-title":"Front Horm Res"},{"key":"BF01875052_CR29","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0040-4039(01)86260-2","volume":"22","author":"G Teutsch","year":"1979","unstructured":"Teutsch G, B\u00e9langer A. Regio and stereospecific synthesis of 11\u03b2-substituted 19-norsteroids. Tetrahedron Lett 1979;22: 2051\u20134.","journal-title":"Tetrahedron Lett"},{"key":"BF01875052_CR30","first-page":"71","volume-title":"Clinical applications of mifepristone, RU 486 and other antiprogestins","author":"EE Baulieu","year":"1993","unstructured":"Baulieu EE. RU 486 \u2014 a decade on today, and tomorrow. In: Donaldson MS, Dorflinger L, Brown SS, Benet LZ, editors. Clinical applications of mifepristone, RU 486 and other antiprogestins. Washington: National Academy Press, 1993:71\u2013119."},{"key":"BF01875052_CR31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/j.2326-1951.1992.tb02404.x","volume":"32","author":"B Benhamou","year":"1992","unstructured":"Benhamou B, Garcia T, Lerouge T, Vergezac A, Gofflo D, Bigogne C, et al.. A single amino acid that determines the sensitivity of progesterone receptors to RU 486. Science 1992;32:45\u201351.","journal-title":"Science"},{"key":"BF01875052_CR32","first-page":"2071","volume":"6","author":"T Garcia","year":"1992","unstructured":"Garcia T, Benhamou B, Gofflo D, Vergezac A, Philibert D, Chambon P, et al.. Switching agonistic, antagonistic, and mixed transcriptional responses to 11\u03b2-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol 1992;6:2071\u20138.","journal-title":"Mol Endocrinol"},{"key":"BF01875052_CR33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(92)90234-4","volume":"69","author":"E Vegeto","year":"1992","unstructured":"Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW. The mechanism of RU 486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992;69:703\u201313.","journal-title":"Cell"},{"key":"BF01875052_CR34","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1210\/jcem-72-5-1060","volume":"72","author":"M Montrella-Waybill","year":"1991","unstructured":"Montrella-Waybill M, Clore JN, Schoolwerth AC, Watlington CO. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991;72:1060\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF01875052_CR35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/ki.1992.421","volume":"42","author":"J Clore","year":"1992","unstructured":"Clore J, Schoolwerth A, Watlington CO. When is cortisol a mineralocorticoid? [editorial]. Kidney Int 1992;42:1297\u2013308.","journal-title":"Kidney Int"},{"key":"BF01875052_CR36","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jcem-25-8-1015","volume":"25","author":"S Ulick","year":"1965","unstructured":"Ulick S, Vetter KK. Simultaneous measurement of the secretory rates of aldosterone and 18-hydroxycorticosterone. J Clin Endocrinol Metab 1965;25:1915\u201326.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF01875052_CR37","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1210\/endo-117-6-2424","volume":"117","author":"SL Dale","year":"1985","unstructured":"Dale SL, Holbrook MM, Melby JC. 19-Nordeoxycorticosterone excretion in rats bred for susceptibility and resistance to the hypertensive effects of salt. Endocrinology 1985;117:2424\u20137.","journal-title":"Endocrinology"},{"key":"BF01875052_CR38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0039-128X(91)90035-T","volume":"56","author":"EP Gomez-Sanchez","year":"1991","unstructured":"Gomez-Sanchez EP, Gomez-Sanchez CE. 19-Nordeoxycorticosterone, aldosterone and corticosterone excretion in sequential urine samples from male and female rats. Steroids 1991;56:451\u20134.","journal-title":"Steroids"},{"key":"BF01875052_CR39","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1021\/jm00392a022","volume":"30","author":"S Kamata","year":"1987","unstructured":"Kamata S, Matsui T, Haga N, Nakamura M, Odaguchi K, Itoh T. Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dihydropregnane derivatives. J Med Chem 1987;30:1647\u201358.","journal-title":"J Med Chem"},{"key":"BF01875052_CR40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0022-4731(83)80047-8","volume":"19","author":"H Sekihara","year":"1983","unstructured":"Sekihara H. 19-hydroxyandrostenedione: a potent hypertensinogenic steroid in man. J Ster Biochem 1983;19:353\u20138.","journal-title":"J Ster Biochem"},{"key":"BF01875052_CR41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1210\/jcem-61-2-291","volume":"61","author":"H Sekihara","year":"1985","unstructured":"Sekihara H, Torii R, Osawa Y, Takaku F. Angiotensin II induces the release of 19-hydroxyandrostenedione in man. J Clin Endocrinol Metab 1985;61:291\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF01875052_CR42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0039-128X(90)90024-6","volume":"55","author":"SA Latif","year":"1990","unstructured":"Latif SA, Conca TJ, Morrris DJ. The effects of the licorice derivative, glycyrrhetinic acid, on hepatic 3\u03b1- and 3\u03b2-hydroxysteroid dehydrogenases and 5\u03b1- and 5\u03b2-reductase pathways of metabolism of aldosterone in male rats. Steroids 1990;55:52\u20138.","journal-title":"Steroids"},{"key":"BF01875052_CR43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ki.1990.258","volume":"38","author":"K Hierholzer","year":"1990","unstructured":"Hierholzer K, Siebe H, Fromm M. Inhibition of 11\u03b2-hydroxysteroid dehydrogenase and its effect on epithelial sodium transport. Kidney Int 1990;38:673\u20138.","journal-title":"Kidney Int"},{"key":"BF01875052_CR44","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0006-2952(91)90176-6","volume":"41","author":"Y Hayashi","year":"1991","unstructured":"Hayashi Y, Hirai S, Negishi M, Okumura T, Ichikawa A. Desensitization by glycyrrhetinic acid of other stimulatory substance-induced increases in intracellular calcium in a variety of cell types. Biochem Pharmacol 1991;41:1725\u201330.","journal-title":"Biochem Pharmacol"},{"key":"BF01875052_CR45","first-page":"E1125","volume":"263","author":"EP Gomez-Sanchez","year":"1992","unstructured":"Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol 1992:263:E1125\u201330.","journal-title":"Am J Physiol"},{"key":"BF01875052_CR46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.290.6461.13","volume":"290","author":"PB Rylance","year":"1985","unstructured":"Rylance PB, Brincat M, Lafferty K, de Traffords JC, Brincat S, Parsons V, et al.. Natural progesterone and antihypertensive action. BMJ 1985;290:13\u20134.","journal-title":"BMJ"},{"key":"BF01875052_CR47","first-page":"99","volume-title":"The adrenal and hypertension: from cloning to clinic. Serono Symposia Publication","author":"JW Funder","year":"1989","unstructured":"Funder JW, Pearce PT, Smith RE, Smith AI. Adrenal steroid and circulatory control: receptor and effector studies. In: Mantero F, Takeda R, Scoggins BA, Biglieri EG, Funder JW, editors. The adrenal and hypertension: from cloning to clinic. Serono Symposia Publication. New York: Raven Press, 1989:99\u2013108."},{"key":"BF01875052_CR48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1210\/endo-67-1-125","volume":"67","author":"CM Kagawa","year":"1960","unstructured":"Kagawa CM. Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. Endocrinology 1960;67:125\u201331.","journal-title":"Endocrinology"},{"key":"BF01875052_CR49","first-page":"902","volume":"77","author":"M Buren van","year":"1993","unstructured":"van Buren M, Boer P, Koomans HA. Effects of acute mineralocorticoid and glucocorticoid receptor blockade on the excretion of an acute potassium load in healthy humans. J Clin Endocrinol Metab 1993;77:902\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF01875052_CR50","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/BF01428394","volume":"44","author":"M Tepel","year":"1993","unstructured":"Tepel M, Husseini S, Zidek W. Effect of spironolactone on cytosolic free sodium concentration in platelets from hypertensive patients with primary aldosteronism. Eur J Clin Pharmacol 1993;44:S51\u20132.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF01875052_CR51","volume-title":"Adrenal steroid antagonism","author":"G Wambach","year":"1984","unstructured":"Wambach G, Casals-Stenzel J. Structure-activity relationship of spironolactone derivatives. In: Agarwal MK, editor. Adrenal steroid antagonism. Berlin: Walter de Gruyter, 1984."},{"key":"BF01875052_CR52","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1210\/endo-104-4-1194","volume":"104","author":"M Claire","year":"1979","unstructured":"Claire M, Rafestin-Oblin ME, Milhaud A, Roth-Meyer C, Corvol P. Mechanism of action of a new antialdosterone compound prorenone. Endocrinology 1979;104:1194\u2013200.","journal-title":"Endocrinology"},{"key":"BF01875052_CR53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/B978-0-12-452812-3.50016-6","volume-title":"Biochemical action of hormones","author":"D Marver","year":"1985","unstructured":"Marver D. The mineralocorticoid receptor. Biochemical action of hormones. Orlando: Academic Press, 1985:385\u2013431."},{"key":"BF01875052_CR54","first-page":"450","volume":"194","author":"LM Hofmann","year":"1975","unstructured":"Hofmann LM, Chinn LJ, Pedrera HA, Krupnick MI, Suley-Manov OD. Potassium prorenoate: a new steroidal aldosterone antagonist. J Pharmacol Exp Ther 1975;194:450\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF01875052_CR55","first-page":"6020","volume":"210","author":"L Ramsay","year":"1977","unstructured":"Ramsay L, Harrison I, Shelton J, Tidd M. Relative potency of prorenoate and spironolactone in normal man. Clin Pharmacol Ther 1977;210:6020\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"BF01875052_CR56","first-page":"650","volume":"240","author":"M Gasparo de","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al.. Three new epoxyspirolactone derivatives; characteristicsin vitro andin vivo. J Pharmacol Exp Ther 1987;240:650\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF01875052_CR57","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0024-3205(88)90402-X","volume":"43","author":"W Sutanto","year":"1988","unstructured":"Sutanto W, de Kloet ER. ZK 91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (Type I) receptors in the rat. Life Sci 1988;43:1537\u201343.","journal-title":"Life Sci"},{"key":"BF01875052_CR58","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1358\/dof.1989.014.11.109653","volume":"14","author":"W Sutanto","year":"1989","unstructured":"Sutanto W, de Kloet ER. ZK 91587 and structurally related antimineralocorticoids. Drugs Future 1989;14:1093\u2013100.","journal-title":"Drugs Future"},{"key":"BF01875052_CR59","first-page":"1583","volume":"36","author":"W Losert","year":"1986","unstructured":"Losert W, Bittler D, Buse M, Casals-Stenzel J, Haberey M, Laurent H, et al.. Mespirenone and other 15,16-methylene-1 7-spirolactones, a new type of steroidal aldosterone antagonists. Arzneimittelforschung\/Drug Res 1986;36:1583\u2013600.","journal-title":"Arzneimittelforschung\/Drug Res"},{"key":"BF01875052_CR60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1021\/jm00164a007","volume":"33","author":"K Nickisch","year":"1990","unstructured":"Nickisch K, Bittler D, Laurent H, Losert W, Nishino Y, Schillinger E, et al.. Aldosterone antagonists. 3. Synthesis and activities of steroidal 7\u03b1-(alkoxycarbonyl)-15,16-methylene spirol. J Med Chem 1990;33:509\u201313.","journal-title":"J Med Chem"},{"key":"BF01875052_CR61","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/jm50001a002","volume":"28","author":"K Nickisch","year":"1985","unstructured":"Nickisch K, Bittler D, Casals-Stenzel J, Laurent H, Nickolson R, Nishino Y, et al.. Aldosterone antagonists. 1. Synthesis and activities of 6\u03b2,7\u03b2;15\u03b2;16\u03b2-dimethylene steroidal spirolactones. J Med Chem 1985;28:546\u201350.","journal-title":"J Med Chem"},{"key":"BF01875052_CR62","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1021\/jm00112a022","volume":"34","author":"K Nickisch","year":"1991","unstructured":"Nickisch K, Beier S, Bittler D, Elger W, Laurent H, Losert W, et al.. Aldosterone antagonists. 4. Synthesis and activities of steroidal 6,6-ethylene-15,16-methylene 17-spirolactones. J Med Chem 1991;34:2464\u20138.","journal-title":"J Med Chem"},{"key":"BF01875052_CR63","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0010-7824(92)90121-9","volume":"46","author":"K Pollow","year":"1992","unstructured":"Pollow K, Juchem M, Elger W, Jacobi N, Hoffmann G, Mobus V. Dihydrospirorenone (ZK 30595): a novel synthetic progestagen \u2014 characterization of binding to different receptor proteins. Contraception 1992;46:561\u201374.","journal-title":"Contraception"},{"key":"BF01875052_CR64","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1210\/endo-109-4-1164","volume":"109","author":"P Komanicky","year":"1981","unstructured":"Komanicky P, Melby JC. Experimental hypertension induced by 19-norprogesterone in rat. Endocrinology 1981;109:1164\u20138.","journal-title":"Endocrinology"},{"key":"BF01875052_CR65","first-page":"167","volume-title":"Antihormones","author":"C Wambach","year":"1979","unstructured":"Wambach C, Higgins JR. Antimineralocorticoid action of progesterone. In: Agarwal MK, editor. Antihormones. Amsterdam: Elsevier\/North-Holland, 1979:167\u201381."},{"key":"BF01875052_CR66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/hbeh.1993.1013","volume":"27","author":"SM Korte","year":"1993","unstructured":"Korte SM, Bouws GA, Bohus B. Central actions of corticotropin-releasing hormone (CRH) on behavioral, neuroendocrine, and cardiovascular regulation: brain corticoid receptor involvement. Horm Behav 1993;27:167\u201383.","journal-title":"Horm Behav"},{"key":"BF01875052_CR67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000419639","volume":"19","author":"MK Agarwal","year":"1991","unstructured":"Agarwal MK. Purification and properties of the mineralocorticoid receptor with the aid of synthetic antisteroids. Front Horm Res 1991;19:55\u201364.","journal-title":"Front Horm Res"},{"key":"BF01875052_CR68","doi-asserted-by":"crossref","first-page":"C875","DOI":"10.1152\/ajpcell.1993.264.4.C875","volume":"264","author":"TJ Schmidt","year":"1993","unstructured":"Schmidt TJ, Husted RF, Stokes JB. Steroid hormone stimulation of Na+ transport in A6 cells is mediated via glucocorticoid receptors. Am J Physiol 1993;264:C875\u201384.","journal-title":"Am J Physiol"},{"key":"BF01875052_CR69","first-page":"F108","volume":"266","author":"H Garty","year":"1994","unstructured":"Garty H, Peterson-Yantorno K, Asher C, Civia MM. Effects of corticoid agonists and antagonists on apical Na+ permeability of toad urinary bladder. Am J Physiol 1994;266:F108\u201316.","journal-title":"Am J Physiol"},{"key":"BF01875052_CR70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0960-0760(93)90337-V","volume":"45","author":"H Sekihara","year":"1993","unstructured":"Sekihara H, Yazaki Y. 5\u03b1-Dihydro-11-deoxycorticosterone as a mineralocorticoid agonist and antagonist: evidence for a weak mineralocorticoid as an antagonist of potent mineralocorticoids. J Ster Biochem Mol Biol 1993;45:235\u20138.","journal-title":"J Ster Biochem Mol Biol"},{"key":"BF01875052_CR71","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1021\/ja01574a058","volume":"79","author":"JA Cella","year":"1957","unstructured":"Cella JA, Kagawa CM. Spironolactone. J Am Chem Soc 1957;79:4808\u201311.","journal-title":"J Am Chem Soc"},{"key":"BF01875052_CR72","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/anie.198206961","volume":"211","author":"D Bittler","year":"1982","unstructured":"Bittler D, Hofmeister H, Laurent H, Nickisch K, Nickolson R, Petzolot K, et al.. Synthesis of spirorenone: a novel highly active aldosterone antagonist. Angew Chem Int Ed Engl 1982;211:696\u20137.","journal-title":"Angew Chem Int Ed Engl"},{"key":"BF01875052_CR73","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0006-291X(88)90541-4","volume":"150","author":"MK Agarwal","year":"1988","unstructured":"Agarwal MK, Kalimi M. Different mechanisms for the receptor mediated antimineralocorticoid action of two new spirolactone derivatives. Biochem Biophys Res Commun 1988; 150:449\u201355.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF01875052_CR74","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1021\/jm00391a023","volume":"30","author":"K Nickisch","year":"1987","unstructured":"Nickisch K, Bittler D, Laurent H, Losert W, Casals-Stenzel J, Nishino N, et al.. Aldosterone antagonists. 2. New 7\u03b1-(acetylthio)-15,16-methylene spironolactones. Med Chem 1987;30:1403\u20139.","journal-title":"Med Chem"},{"key":"BF01875052_CR75","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0006-291X(86)90556-5","volume":"134","author":"G Lazar","year":"1986","unstructured":"Lazar G, Agarwal MK. Evidence for an antagonist specific receptor that does not bind mineralocorticoid agonists. Biochem Biophys Res Commun 1986;134:261\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF01875052_CR76","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0006-291X(87)90679-6","volume":"143","author":"MK Agarwal","year":"1987","unstructured":"Agarwal MK, Kalimi M. Activation of mineralocorticoid agonist and antagonist specific receptors from rat kidney. Biochem Biophys Res Commun 1987;143:398\u2013402.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF01875052_CR77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0006-8993(85)91291-0","volume":"361","author":"H Coirini","year":"1985","unstructured":"Coirini H, Magarinos AM, de Nicola AF, Rainbow TC, McEwen BS. Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markersin vivo. Brain Res 1985;361:212\u20136.","journal-title":"Brain Res"},{"key":"BF01875052_CR78","doi-asserted-by":"crossref","unstructured":"Torelli V, Hardy M, Nedelec L, Tournemine C, Deraedt C, Philibert D. 7\u03b1-Alkyl steroidal spirolactones as potent aldosterone antagonists [abstract]. J Ster Biochem 1982;17:Abstr 198.","DOI":"10.1016\/0022-4731(82)90412-5"},{"key":"BF01875052_CR79","first-page":"E737","volume":"258","author":"M Kalimi","year":"1990","unstructured":"Kalimi M, Opoku J, Agarwal MK, Corley K. Effects of antimineralocorticoid RU 26752 on steroid-induced hypertension in rats. Am J Physiol 1990;258:E737\u20139.","journal-title":"Am J Physiol"},{"key":"BF01875052_CR80","unstructured":"Philibert D, Moguilewsky M. RU 28362, a useful tool for the characterization of glucocorticoid and mineralocorticoid receptors [abstract]. Proceedings of the 65th Annual Meeting of the Endocrinology Society 1983;335:Abstr 1018."},{"key":"BF01875052_CR81","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/1097-0142(19901101)66:9<1949::AID-CNCR2820660917>3.0.CO;2-E","volume":"66","author":"I Lang","year":"1990","unstructured":"Lang I, Zielinski CC, Templ H, Spona J, Geyer G. Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor. Cancer 1990;66:1949\u201353.","journal-title":"Cancer"},{"key":"BF01875052_CR82","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1210\/endo-107-5-1393","volume":"107","author":"GP Guthrie Jr","year":"1980","unstructured":"Guthrie GP Jr, John WJ. Thein vivo glucocorticoid and antiglucocorticoid actions of medroxyprogesterone acetate. Endocrinology 1980;107:1393\u20139.","journal-title":"Endocrinology"},{"key":"BF01875052_CR83","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1210\/endo-114-6-1983","volume":"114","author":"HP Schane","year":"1984","unstructured":"Schane HP, Harding HR, Creange JE, Botton I, Castracane VD, Snyder BW. Nivazol: a glucocorticoid in rats with only hypothalamic-pituitary-adrenal-inhibiting activity in primates. Endocrinology 1984;114:1983\u20139.","journal-title":"Endocrinology"},{"key":"BF01875052_CR84","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1210\/endo-117-4-1355","volume":"117","author":"JA Schlechte","year":"1985","unstructured":"Schlechte JA, Simons SS Jr, Lewis DA, Thompson EB. [3H]-Cortivasol: a unique high affinity ligand for the glucocorticoid receptor. Endocrinology 1985;117:1355\u201362.","journal-title":"Endocrinology"},{"key":"BF01875052_CR85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0960-0760(93)90082-8","volume":"44","author":"T Burolaud","year":"1993","unstructured":"Burolaud T, Danze PM, Tbarka N, Formstecher P, Dautrevaux M. Binding of RU 486 and deacylcortivazol to the glucocorticoid receptor is insensitive to sulfhydryl-modifying agents. J Ster Biochem Mol Biol 1993;44:217\u201325.","journal-title":"J Ster Biochem Mol Biol"},{"key":"BF01875052_CR86","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1210\/endo-114-6-2252","volume":"114","author":"N Lamontagne","year":"1984","unstructured":"Lamontagne N, Mercier L, Pons M, Thompson EB, Simon SS Jr.. Glucocorticoid versus antiglucocorticoid activity: can a single functional group modification of glucocorticoid steroids always convey antiglucocorticoid activity? Endocrinology 1984;114:2252\u201363.","journal-title":"Endocrinology"},{"key":"BF01875052_CR87","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0022-4731(86)90242-6","volume":"25","author":"D Gagne","year":"1986","unstructured":"Gagne D, Pons M, De Paulet AC. Analysis of the relation between receptor binding affinity and antagonist efficacy of antiglucocorticoids. J Ster Biochem 1986;25:315\u201322.","journal-title":"J Ster Biochem"},{"key":"BF01875052_CR88","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1210\/mend-1-9-659","volume":"1","author":"H Richard-Foy","year":"1987","unstructured":"Richard-Foy H, Sistare FD, Riegel AT, Simons SS Jr, Hager GL. Mechanism of dexamethasone 21-mesylate antiglucocorticoid action: II. Receptor-antiglucocorticoid complexes do not interact productively with mouse mammary tumor virus long terminal repeat chromatin. Mol Endocrinol 1987;1:659\u201365.","journal-title":"Mol Endocrinol"},{"key":"BF01875052_CR89","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1210\/mend-1-9-648","volume":"1","author":"FD Sistare","year":"1987","unstructured":"Sistare FD, Hager GL, Simons Jr SS. Mechanism of dexamethasone 21-mesylate antiglucocorticoid action: I. Receptor-antiglucocorticoid complexes do not competitively inhibit receptor-glucocorticoid complex activation of gene transcriptionin vivo. Mol Endocrinol 1987;1:648\u201358.","journal-title":"Mol Endocrinol"},{"key":"BF01875052_CR90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0960-0760(92)90186-M","volume":"43","author":"SS Simons Jr","year":"1992","unstructured":"Simons SS Jr, Oshima H, Szapary D. Modulation of the agonist activity of antisteroids by a novel cis-acting element. J Ster Biochem Mol Biol 1992;43:43\u201355.","journal-title":"J Ster Biochem Mol Biol"},{"key":"BF01875052_CR91","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/endo.130.1.1309341","volume":"130","author":"B Couette","year":"1992","unstructured":"Couette B, Marsaud V, Baulieu EE, Richard-Foy H, Rafestin-Oblin ME. Spironolactone, an aldosterone antagonist, acts as an antiglucocorticoid on the mouse mammary tumor virus promoter. Endocrinology 1992;130:430\u20136.","journal-title":"Endocrinology"},{"key":"BF01875052_CR92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0960-0760(93)90345-W","volume":"45","author":"RM Bigsby","year":"1993","unstructured":"Bigsby RM. Progesterone and dexamethasone inhibition of estrogen-induced synthesis of DNA and complement in rat uterine epithelium: effects of antiprogesterone compounds. J Ster Biochem Mol Biol 1993;45:295\u2013301.","journal-title":"J Ster Biochem Mol Biol"},{"key":"BF01875052_CR93","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1021\/jm00110a002","volume":"34","author":"S Lopez","year":"1991","unstructured":"Lopez S, Simons SS Jr. Dexamethasone 21-(\u03b2-isothiocyanatoethyl) thioester: a new affinity label for glucocorticoid receptors. J Med Chem 1991;34:1762\u20137.","journal-title":"J Med Chem"},{"issue":"Suppl 26","key":"BF01875052_CR94","first-page":"S18","volume":"34","author":"GP Chrousos","year":"1988","unstructured":"Chrousos GP, Laue L, Nieman LK, Kawai S, Udelsman RU, Brandon DD, et al.. Glucocorticoids and glucocorticoid antagonists: lessons from RU 486. Kidney Int 1988;34 Suppl 26:S18\u201323.","journal-title":"Kidney Int"},{"key":"BF01875052_CR95","first-page":"417","volume":"266","author":"BA Fuchs","year":"1993","unstructured":"Fuchs BA, Pruett SB. Morphine induces apoptosis in murine thymocytesin vivo but notin vitro: involvement of both opiate and glucocorticoid receptors. J Pharmacol Exp Ther 1993;266:417\u201323.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF01875052_CR96","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0006-8993(93)90042-L","volume":"615","author":"DF Papolos","year":"1993","unstructured":"Papolos DF, Edwards E, Marmur R, Lachman HM, Henn FA. Effects of the antiglucocorticoid RU 38486 on the induction of learned helplessness behavior in Sprague-Dawley rats. Brain Res 1993;615:304\u20139.","journal-title":"Brain Res"},{"key":"BF01875052_CR97","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1037\/0735-7044.106.1.62","volume":"106","author":"MS Oitzl","year":"1992","unstructured":"Oitzl MS, de Kloet ER. Selective corticosteroid antagonists modulate specific aspects of spatial orientation learning. Behav Neurosci 1992;106:62\u201371.","journal-title":"Behav Neurosci"},{"key":"BF01875052_CR98","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0165-3806(93)90145-Z","volume":"73","author":"SJ Yi","year":"1993","unstructured":"Yi SJ, Masters JN, Baram TZ. Effects of a specific glucocorticoid receptor antagonist on corticotropin releasing hormone gene expression in the paraventricular nucleus of the neonatal rat. Dev Brain Res 1993;73:253\u20139.","journal-title":"Dev Brain Res"},{"key":"BF01875052_CR99","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0022-4731(88)90156-2","volume":"29","author":"L Laue","year":"1988","unstructured":"Laue L, Kawai S, Brandon D, Brightwell D, Barnes K, Knazek RA, et al.. Receptor-mediated effects of glucocorticoids on inflammation: enhancement of the inflammatory response with a glucocorticoid antagonist. J Ster Biochem 1988;29:591\u20139.","journal-title":"J Ster Biochem"},{"key":"BF01875052_CR100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-5793(92)81261-J","volume":"308","author":"G Lazar Jr","year":"1992","unstructured":"Lazar G Jr, Duda E, Lazar G. Effect of RU 38486 on TNF production and toxicity. FEBS Lett 1992;308:137\u201340.","journal-title":"FEBS Lett"},{"key":"BF01875052_CR101","first-page":"R1010","volume":"264","author":"LE Morrow","year":"1993","unstructured":"Morrow LE, McClellan JL, Conn CA, Kluger MJ. Glucocorticoids alter fever and II-6 responses to psychological stress and to lipopolysaccharide. Am J Physiol 1993;264:R1010\u20136.","journal-title":"Am J Physiol"},{"key":"BF01875052_CR102","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000125046","volume":"48","author":"A Ratka","year":"1988","unstructured":"Ratka A, Sutanto W, de Kloet ER. Long-term glucocorticoid suppression of opioid-induced antinociception. Neuroendocrinology 1988;48:439\u201344.","journal-title":"Neuroendocrinology"},{"key":"BF01875052_CR103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0024-3205(92)90521-P","volume":"51","author":"A Capasso","year":"1992","unstructured":"Capasso A, Di Giannuario A, Loizzo A, Pieretti S, Sorrentino L. Central interaction of dexamethasone and RU 38486 on morphine antinociception in mice. Life Sci 1992;51:139\u201343.","journal-title":"Life Sci"},{"key":"BF01875052_CR104","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000419638","volume":"19","author":"AM Etgen","year":"1991","unstructured":"Etgen AM, Vathy I. Agonist and antagonist effects of RU 38486 on progesterone-regulated sexual behavior and neurochemical responses. Front Horm Res 1991;19:45\u201354.","journal-title":"Front Horm Res"},{"key":"BF01875052_CR105","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1006\/hbeh.1993.1035","volume":"27","author":"ET Pleim","year":"1993","unstructured":"Pleim ET, Lipetz J, Steele TL, Barfield RJ. Facilitation of sexual receptivity by ventromedial hypothalamic implants of the antiprogestin RU 486. Horm Behav 1993;27:488\u201398.","journal-title":"Horm Behav"},{"key":"BF01875052_CR106","first-page":"731","volume":"7","author":"SK Nordeen","year":"1993","unstructured":"Nordeen SK, Bona BJ, Moyer ML. Latent agonist activity of the steroid antagonist, RU 486, is unmasked in cells treated with activators of protein kinase A. Mol Endocrinol 1993;7:731\u201342.","journal-title":"Mol Endocrinol"},{"key":"BF01875052_CR107","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1210\/endo.133.2.8344212","volume":"133","author":"CA Beck","year":"1993","unstructured":"Beck CA, Estes PA, Bona BJ, Muro-Cacho CA, Nordeen SK, Edwards DP. The steroid antagonist RU 486 exerts different effects on the glucocorticoid and progesterone receptors. Endocrinology 1993;133:728\u201340.","journal-title":"Endocrinology"},{"key":"BF01875052_CR108","first-page":"22","volume":"120","author":"KT Weber","year":"1992","unstructured":"Weber KT. Glucocorticoids and mineralocorticoids: antifibrotic and profibrotic of wound healing. J Lab Clin Med 1992;120:22\u20139.","journal-title":"J Lab Clin Med"},{"key":"BF01875052_CR109","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/21548331.1992.11705486","volume":"27","author":"JD Baxter","year":"1992","unstructured":"Baxter JD. The effect of glucocorticoid therapy. Hosp Pract 1992;27:111\u201323.","journal-title":"Hosp Pract"},{"key":"BF01875052_CR110","first-page":"22","volume-title":"Contemporary trends in diuretic therapy","author":"A Karim","year":"1986","unstructured":"Karim A. Spironolactone metabolism in man revisited. In: Brunner HR, Berglund G, Brutsaert DL, Cardiner P, Ledingham JGG, editors. Contemporary trends in diuretic therapy. Amsterdam: Excerpta Medica, 1986:22\u201337."},{"key":"BF01875052_CR111","volume-title":"Hormone antagonists","author":"LE Ramsay","year":"1982","unstructured":"Ramsay LE. Clinical pharmacology and therapeutic use of aldosterone antagonists. In: Agarwal MK, editor. Hormone antagonists. Berlin: Walter de Gruyter, 1982."},{"key":"BF01875052_CR112","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000199198","volume":"31","author":"M Bernardi","year":"1985","unstructured":"Bernardi M, Servadei D, Trevisani F, Rusticali AG, Gasbarrini G. Importance of plasma aldosterone concentration in patients with liver cirrhosis and ascites. Digestion 1985;31:189\u201393.","journal-title":"Digestion"},{"issue":"II","key":"BF01875052_CR113","first-page":"1492","volume":"38","author":"M Emili","year":"1988","unstructured":"Emili M, Cuppone R, Ricci GL. Comparative clinical study of spironolactone and potassium canrenoate: a randomized evaluation with double cross-over test. Arzneimittelforschung\/Drug Res 1988;38(II):1492\u20135.","journal-title":"Arzneimittelforschung\/Drug Res"},{"key":"BF01875052_CR114","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0002-8703(78)90052-2","volume":"96","author":"HR Ochs","year":"1978","unstructured":"Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Spironolactone. Am Heart J 1978;96:389\u2013400.","journal-title":"Am Heart J"},{"key":"BF01875052_CR115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00000441-197012000-00001","volume":"260","author":"MG Crane","year":"1970","unstructured":"Crane MG, Harris JJ. Effects of spironolactone in hypertensive patients. Am J Med Sci 1970;260:311\u201330.","journal-title":"Am J Med Sci"},{"issue":"Suppl 26","key":"BF01875052_CR116","first-page":"S14","volume":"34","author":"X Jeunemaitre","year":"1988","unstructured":"Jeunemaitre X, Kreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P-F, et al.. Long-term effect of spironolactone in essential hypertension. Kidney Int 1988;34 Suppl 26:S14\u20139.","journal-title":"Kidney Int"},{"key":"BF01875052_CR117","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0022-4731(89)90166-0","volume":"32","author":"S Ulick","year":"1989","unstructured":"Ulick S, Chan SK, Nageswara Rao K, Edassery J, Mantero F. A new form of the syndrome of apparent mineralocorticoid excess. J Ster Biochem 1989;32:209\u201312.","journal-title":"J Ster Biochem"},{"key":"BF01875052_CR118","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2133.1985.tb02305.x","volume":"112","author":"BM Burke","year":"1985","unstructured":"Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985;112:124\u20135.","journal-title":"Br J Dermatol"},{"key":"BF01875052_CR119","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM198902233200805","volume":"320","author":"L Laue","year":"1989","unstructured":"Laue L, Kenisberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, et al.. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989;320:496\u2013502.","journal-title":"N Engl J Med"},{"key":"BF01875052_CR120","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/0003-4819-85-5-630","volume":"85","author":"DL Loriaux","year":"1976","unstructured":"Loriaux DL, Menard R, Taylor A, Pita JC, Santen R. Spironolactone and endocrine dysfunction. Ann Intern Med 1976:85:630\u20136.","journal-title":"Ann Intern Med"},{"key":"BF01875052_CR121","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.1973.03220280028007","volume":"225","author":"DJ Greenblatt","year":"1973","unstructured":"Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program. JAMA 1973;225:40\u20133.","journal-title":"JAMA"},{"key":"BF01875052_CR122","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","volume":"32","author":"M Gasparo de","year":"1989","unstructured":"de Gasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P, Menard J. Antialdosterones: incidence and prevention of sexual side-effects. J Ster Biochem 1989;32:223\u20137.","journal-title":"J Ster Biochem"},{"key":"BF01875052_CR123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0015-0282(16)60807-5","volume":"52","author":"ST Nakajima","year":"1989","unstructured":"Nakajima ST, Brumsted JR, Riddick DH, Gibson M. Absence of progestational activity of oral spironolactone. Fertil Steril 1989;52:155\u20138.","journal-title":"Fertil Steril"},{"key":"BF01875052_CR124","first-page":"686","volume":"185","author":"W Sadee","year":"1973","unstructured":"Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in human. J Pharmacol Exp Ther 1973;185:686\u201395.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF01875052_CR125","first-page":"212","volume":"201","author":"CS Cook","year":"1988","unstructured":"Cook CS, Hauswald CL, Schoenhard GL, Piper CE, Patel A, Radzialowski FM, et al.. Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate. Arch Toxicol 1988;201:212\u20134.","journal-title":"Arch Toxicol"},{"key":"BF01875052_CR126","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/BF00544063","volume":"28","author":"A Ulmann","year":"1985","unstructured":"Ulmann A, Bertagna C, Le Go A, Husson JM, Tache A, Sassano P, et al.. Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism. Eur J Clin Pharmacol 1985;28:531\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF01875052_CR127","first-page":"412","volume-title":"Proceedings of the Searle Symposium","author":"JA Millar","year":"1978","unstructured":"Millar JA, Cumming AMM, Fraser R, Mason PA, Leckie BJ, Morton JJ, et al. Plasma active and inactive renin, angiotensin II and aldosterone concentrations in normal subjects during administration of spironolactone. Proceedings of the Searle Symposium. Amsterdam: Excerpta Medica, 1978:412\u20139."},{"key":"BF01875052_CR128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1515\/9783110846935-009","volume-title":"Receptor-mediated antisteroid action","author":"G Wambach","year":"1987","unstructured":"Wambach G. The mineralocorticoid receptor and the activity of aldosterone antagonists. In: Agarwal MK, editor. Receptor-mediated antisteroid action. Berlin: Walter de Gruyter, 1987:169\u201396."},{"key":"BF01875052_CR129","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","volume":"61","author":"LK Nieman","year":"1985","unstructured":"Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula B, Cutler GB Jr, et al.. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985;61:536\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF01875052_CR130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/jcem-59-1-25","volume":"59","author":"X Bertagna","year":"1984","unstructured":"Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 1984;59:25\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF01875052_CR131","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jcem-63-3-639","volume":"63","author":"X Bertagna","year":"1986","unstructured":"Bertagna X, Bertagna C, Laudat M-H, Husson J-M, Girard F, Luton JP. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 1986;63:639\u201343.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF01875052_CR132","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000419639","volume":"19","author":"M Kalimi","year":"1991","unstructured":"Kalimi M, Opoku J, Corley K. Role of glucocorticoid antagonist RU 486 and mineralocorticoid antagonist RU 26752 in experimental hypertension in rats. Front Horm Res 1991;19:55\u201364.","journal-title":"Front Horm Res"},{"key":"BF01875052_CR133","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(84)91279-0","volume":"1","author":"CI Phillips","year":"1984","unstructured":"Phillips CI, Green K, Gore S, Cullen PM, Campbell M. Eye drops of RU 486, a peripheral steroid blocker, lower intraocular pressure in rabbit. Lancet 1984;1:767\u20138.","journal-title":"Lancet"},{"key":"BF01875052_CR134","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/01.HYP.7.2.292","volume":"7","author":"JP Gr\u00fcnfeld","year":"1985","unstructured":"Gr\u00fcnfeld JP, Eloy L, Moura AM, Ganeval D, Ramos-Frendo B, Worcel M. Effects of antiglucocorticoids on glucocorticoid hypertension in the rat. Hypertension 1985;7:591\u20139.","journal-title":"Hypertension"},{"key":"BF01875052_CR135","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2265.1988.tb03688.x","volume":"28","author":"X Bertagna","year":"1988","unstructured":"Bertagna X, Basin C, Picard F, Varet B, Bertagna C, Hucher M, et al.. Peripheral antiglucocorticoid action of RU 486 in man. Clin Endocrinol 1988;28:537\u201341.","journal-title":"Clin Endocrinol"},{"key":"BF01875052_CR136","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1210\/jcem-71-6-1474","volume":"71","author":"L Laue","year":"1990","unstructured":"Laue L, Lotze MT, Chrousos GP, Barnes K, Loriaux DL, Fleisher TA. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. J Clin Endocrinol Metab 1990;71:1474\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF01875052_CR137","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/BF02191963","volume":"241","author":"K Wiedemann","year":"1992","unstructured":"Wiedemann K, Lauer C, Loycke A, Pollmacher T, Durst P, Macher JP, et al.. Antiglucocorticoid treatment disrupts endocrine cycle and nocturnal sleep pattern. Eur Arch Psychiatry Clin Neurosci 1992;241:372\u20135.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BF01875052_CR138","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0278-5846(92)90109-R","volume":"16","author":"KR Krishnan","year":"1992","unstructured":"Krishnan KR, Reed D, Wilson WH, Saunders WB, Ritchie JC, Nemeroff CB, et al.. RU 486 in depression. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:913\u201320.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BF01875052_CR139","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.81.12.3879","volume":"81","author":"RC Gaillard","year":"1984","unstructured":"Gaillard RC, Riondel A, Muller AF, Herrmann W, Baulieu EE. RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci USA 1984;81:3879\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF01875052_CR140","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1159\/000126474","volume":"57","author":"MA Kling","year":"1993","unstructured":"Kling MA, Demitrack MA, Whitfield HJ Jr, Kalogeras KT, Listwak SJ, DeBellis MD, et al.. Effects of the glucocorticoid receptor antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients. Neuroendocrinology 1993;57:1082\u201391.","journal-title":"Neuroendocrinology"},{"key":"BF01875052_CR141","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.2422758","volume":"232","author":"MD Majewska","year":"1986","unstructured":"Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptors. Science 1986;232:1004\u20137.","journal-title":"Science"},{"key":"BF01875052_CR142","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2826.1989.tb00111.x","volume":"4","author":"W Sutanto","year":"1989","unstructured":"Sutanto W, Handelmann G, de Bree F, de Kloet ER. Multifaceted interaction of corticosteroids with the intracellular receptors and with membrane GABAA receptor complex in the rat brain. J Neuroendocrinol 1989;4:243\u20137.","journal-title":"J Neuroendocrinol"}],"container-title":["Pharmacy World &amp; Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01875052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01875052\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01875052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T03:47:14Z","timestamp":1586317634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01875052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":142,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["BF01875052"],"URL":"https:\/\/doi.org\/10.1007\/bf01875052","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}